Prestroke Antiplatelet Effect on Symptomatic Intracranial Hemorrhage and Functional Outcome in Intravenous Thrombolysis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Choi, Jay Chol | - |
dc.contributor.author | Lee, Ji Sung | - |
dc.contributor.author | Park, Tai Hwan | - |
dc.contributor.author | Cho, Yong-Jin | - |
dc.contributor.author | Park, Jong-Moo | - |
dc.contributor.author | Kang, Kyusik | - |
dc.contributor.author | Lee, Kyung Bok | - |
dc.contributor.author | Lee, Soo Joo | - |
dc.contributor.author | Kim, Jae Guk | - |
dc.contributor.author | Lee, Jun | - |
dc.contributor.author | Park, Man-Seok | - |
dc.contributor.author | Choi, Kang-Ho | - |
dc.contributor.author | Kim, Joon-Tae | - |
dc.contributor.author | Yu, Kyung-Ho | - |
dc.contributor.author | Lee, Byung-Chul | - |
dc.contributor.author | Oh, Mi-Sun | - |
dc.contributor.author | Cha, Jae-Kwan | - |
dc.contributor.author | Kim, Dae-Hyun | - |
dc.contributor.author | Nah, Hyun-Wook | - |
dc.contributor.author | Kim, Dong-Eog | - |
dc.contributor.author | Ryu, Wi-Sun | - |
dc.contributor.author | Kim, Beom Joon | - |
dc.contributor.author | Bae, Hee-Joon | - |
dc.contributor.author | Kim, Wook-Joo | - |
dc.contributor.author | Shin, Dong-Ick | - |
dc.contributor.author | Yeo, Min-Ju | - |
dc.contributor.author | Il Sohn, Sung | - |
dc.contributor.author | Hong, Jeong-Ho | - |
dc.contributor.author | Lee, Juneyoung | - |
dc.contributor.author | Hong, Keun-Sik | - |
dc.date.accessioned | 2021-09-03T20:25:00Z | - |
dc.date.available | 2021-09-03T20:25:00Z | - |
dc.date.created | 2021-06-16 | - |
dc.date.issued | 2016-09 | - |
dc.identifier.issn | 2287-6391 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/87627 | - |
dc.description.abstract | Background and Purpose About 30%-40% of stroke patients are taking antiplatelet at the time of their strokes, which might increase the risk of symptomatic intracranial hemorrhage (SICH) with intravenous tissue plasminogen activator (IV-TPA) therapy. We aimed to assess the effect of pre stroke antiplatelet on the SICH risk and functional outcome in Koreans treated with IV-TPA. Methods From a prospective stroke registry, we identified patients treated with IV-TPA between October 2009 and November 2014. Prestroke antiplatelet use was defined as taking antiplatelet within 7 days before the stroke onset. The primary outcome was SIGH. Secondary outcomes were discharge modified Rankin Scale (mRS) score and in-hospital mortality. Results Of 1,715 patients treated with IV-TPA, 441 (25.7%) were on prestroke antiplatelet. Pre-stroke antiplatelet users versus non-users were more likely to be older, to have multiple vascular risk factors. Prestroke antiplatelet use was associated with an increased risk of SICH (5.9% vs. 3.0%; adjusted odds ratio [OR] 1.79 [1.05-3.04]). However, at discharge, the two groups did not differ in mRS distribution (adjusted OR 0.90 [0.72-1.14]), mRS 0-1 outcome (34.2% vs. 33.7%; adjusted OR 1.27 [0.94-1.72), mRS 0-2 outcome (52.4% vs. 52.9%; adjusted OR 1.21 [0.90-1.63]), and in-hospital mortality (6.1% vs. 4.2%; adjusted OR 1.19 [0.71-2.01]). Conclusions Despite an increased risk of SICH, prestroke antiplatelet users compared to non-users had comparable functional outcomes and in-hospital mortality with IV-TPA therapy. Our results support the use of IV-TPA in eligible patients taking antiplatelet therapy before their stroke onset. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KOREAN STROKE SOC | - |
dc.subject | ACUTE ISCHEMIC-STROKE | - |
dc.subject | TISSUE-PLASMINOGEN-ACTIVATOR | - |
dc.subject | RANDOMIZED CONTROLLED-TRIALS | - |
dc.subject | INTRACEREBRAL HEMORRHAGE | - |
dc.subject | RISK-FACTORS | - |
dc.subject | THERAPY | - |
dc.subject | METAANALYSIS | - |
dc.subject | MULTICENTER | - |
dc.subject | ADJUSTMENT | - |
dc.subject | REGISTRY | - |
dc.title | Prestroke Antiplatelet Effect on Symptomatic Intracranial Hemorrhage and Functional Outcome in Intravenous Thrombolysis | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, Juneyoung | - |
dc.identifier.doi | 10.5853/jos.2016.00185 | - |
dc.identifier.scopusid | 2-s2.0-84990070376 | - |
dc.identifier.wosid | 000385335500013 | - |
dc.identifier.bibliographicCitation | JOURNAL OF STROKE, v.18, no.3, pp.344 - 351 | - |
dc.relation.isPartOf | JOURNAL OF STROKE | - |
dc.citation.title | JOURNAL OF STROKE | - |
dc.citation.volume | 18 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 344 | - |
dc.citation.endPage | 351 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002150810 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Neurosciences & Neurology | - |
dc.relation.journalResearchArea | Cardiovascular System & Cardiology | - |
dc.relation.journalWebOfScienceCategory | Clinical Neurology | - |
dc.relation.journalWebOfScienceCategory | Peripheral Vascular Disease | - |
dc.subject.keywordPlus | ACUTE ISCHEMIC-STROKE | - |
dc.subject.keywordPlus | TISSUE-PLASMINOGEN-ACTIVATOR | - |
dc.subject.keywordPlus | RANDOMIZED CONTROLLED-TRIALS | - |
dc.subject.keywordPlus | INTRACEREBRAL HEMORRHAGE | - |
dc.subject.keywordPlus | RISK-FACTORS | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | METAANALYSIS | - |
dc.subject.keywordPlus | MULTICENTER | - |
dc.subject.keywordPlus | ADJUSTMENT | - |
dc.subject.keywordPlus | REGISTRY | - |
dc.subject.keywordAuthor | Stroke | - |
dc.subject.keywordAuthor | Thrombolytic therapy | - |
dc.subject.keywordAuthor | Platelet aggregation inhibitors | - |
dc.subject.keywordAuthor | Outcome assessment | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.